Experimental Weight-Loss Drug Shows Promising Results in Clinical Trials
Eloralintide, an experimental medication developed by Eli Lilly in Indianapolis, has demonstrated significant weight loss in a Phase 2 clinical trial, with participants losing up to 20% of their body weight over 48 weeks. The drug, which targets the amylin receptor, showed improvements in various health markers and is now moving to Phase 3 trials.
According to a study published in The Lancet and presented at ObesityWeek 2025 in Atlanta, Georgia, the drug led to